Chronic Myeloid Leukemia: Clinical Trials

53 trials for Chronic Myeloid Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 completed, 9 recruiting, 6 terminated, 5 withdrawn. 53 Phase 1, 19 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 153Completed 25, Recruiting 9, Terminated 6, Withdrawn 5, Unknown 4, Active not recruiting 3, Suspended 1
Phase 219Completed 6, Terminated 4, Unknown 4, Withdrawn 4, Recruiting 1

Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia

Trials (filtered) newest first · largest first

All 53 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies
Phase 1RecruitingUniversity of Wisconsin, Madison222026-11-012026-11-12
Prophylactic DLI-X for Leukemia Relapse After HCT
Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Phase 1RecruitingUniversity of Arizona1802026-10-262026-10-29
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
CBX-250 - High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML)
Phase 1RecruitingCrossbow Therapeutics, Inc.722025-07-162026-03-16
TGRX-678 Pharmacokinetic Mass Balance
[14C]TGRX-678 - Chronic Myeloid Leukemia
Phase 1CompletedShenzhen TargetRx Co., Ltd.62025-07-072025-09-04
TGRX-678 Phase I Oral Pharmacokinetic Study
TGRX-678 - Chronic Myeloid Leukemia
Phase 1CompletedShenzhen TargetRx Co., Ltd.762024-11-242025-05-16
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
MK-4208 - Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase
Phase 1 / Phase 2RecruitingTerns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)3302024-03-262026-10-15
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Fludarabine + Total Marrow Irradiation - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Phase 1 / Phase 2WithdrawnNaoyuki G. Saito, M.D., Ph.D.2023-10-012023-12-11
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy
Phase 1SuspendedDavid Wald122022-09-092026-07-14
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes
Phase 1Active not recruitingMacroGenics1302022-07-132026-07-28
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
ELVN-001 - Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Phase 1RecruitingEnliven Therapeutics2502022-05-222026-11-19
KRT-232 and TKI Study in Chronic Myeloid Leukemia
KRT-232, Dasatinib, Nilotinib - Chronic Myeloid Leukemia
Phase 1 / Phase 2UnknownKartos Therapeutics, Inc.1092021-05-072022-03-21
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3 - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 1WithdrawnMedigene AG2020-07-022021-10-08
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion) - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Phase 1RecruitingUniversity of Kansas Medical Center382020-01-312026-03-25
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab - Leukemia, Myeloid, Chronic, Myeloid Leukemia
Phase 1RecruitingAscentage Pharma Group Inc.2422020-01-092025-11-05
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 1Active not recruitingOrca Biosystems, Inc.1552019-11-212026-08-14
Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia
Chronic Myeloid Leukemia + NK cell - Chronic Myeloid Leukemia
Phase 1 / Phase 2UnknownHospital de Clinicas de Porto Alegre52019-03-012019-03-12
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Azacitidine, Selumetinib - Chronic Myeloid Leukemia, Myelofibroses
Phase 1RecruitingUniversity of Chicago182018-09-042025-12-29
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Fludarabine, Total Marrow Irradiation (TMI) - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Phase 1TerminatedNaoyuki G. Saito, M.D., Ph.D.62018-08-292022-03-09
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Natural Killer (NK) Cells, ALT803 - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 1CompletedBrenda Cooper, MD142018-05-222023-02-21
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia
Phase 1RecruitingFred Hutchinson Cancer Center242018-02-232026-05-18

Showing 20 of 53. Sign in to see all of them.

Narrower conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (53)  ·  Leukemia, Myeloid, Acute (23)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (23)  ·  Myelodysplastic Syndromes (22)  ·  Lymphoma, Non-Hodgkin (10)  ·  Multiple Myeloma (8)  ·  Primary Myelofibrosis (7)  ·  Hodgkin Disease (6)  ·  Hematologic Neoplasms (4)  ·  Leukemia (4)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (4)  ·  Leukemia, Myeloid, Chronic-Phase (4)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (3)  ·  Leukemia, Myelomonocytic, Chronic (3)  ·  Blast Crisis (2)

Broader conditions

Bone Marrow Diseases (53)  ·  Chronic Disease (53)  ·  Disease Attributes (53)  ·  Hematologic Diseases (53)  ·  Hemic and Lymphatic Diseases (53)  ·  Neoplasms (53)  ·  Neoplasms by Histologic Type (53)  ·  Pathologic Processes (53)  ·  Pathological Conditions, Signs and Symptoms (53)  ·  Leukemia, Myeloid (51)  ·  Myeloproliferative Disorders (51)  ·  Leukemia (49)  ·  Immune System Diseases (26)  ·  Immunoproliferative Disorders (26)  ·  Lymphatic Diseases (26)

Interventions

Imatinib Mesylate (5)  ·  nilotinib (5)  ·  fludarabine (3)  ·  fludarabine phosphate (3)  ·  Azacitidine (2)  ·  Busulfan (2)  ·  Cyclophosphamide (2)  ·  Cytarabine (2)  ·  Dasatinib (2)  ·  Filgrastim (2)  ·  Granulocyte Colony-Stimulating Factor (2)  ·  1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea (1)  ·  4-fluorobenzoyl-TN-14003 (1)  ·  ALT-803 (1)  ·  AZD 6244 (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  M.D. Anderson Cancer Center (2)  ·  Naoyuki G. Saito, M.D., Ph.D. (2)  ·  Shenzhen TargetRx Co., Ltd. (2)  ·  American Regent, Inc. (1)  ·  Ascentage Pharma Group Inc. (1)  ·  Astex Pharmaceuticals, Inc. (1)  ·  Baylor College of Medicine (1)  ·  Brenda Cooper, MD (1)  ·  Bristol-Myers Squibb (1)  ·  Case Comprehensive Cancer Center (1)  ·  Cellerant Therapeutics (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  Chong Kun Dang Pharmaceutical (1)  ·  Crossbow Therapeutics, Inc. (1)

Countries

United States (33)  ·  Germany (9)  ·  France (8)  ·  South Korea (6)  ·  Italy (5)  ·  Canada (4)  ·  Israel (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  China (3)  ·  Netherlands (3)  ·  Belgium (2)  ·  Poland (2)  ·  Russia (2)

Top investigators

Jorge Cortes, MD (3)  ·  Andreas Hochhaus, Prof. Dr. med. (1)  ·  Anna Turkina, Professor (1)  ·  Arnon Nagler, MD (1)  ·  Ashok Srinivasan, MD (1)  ·  B. Douglas Smith, MD (1)  ·  Benjamin Tomlinson, MD (1)  ·  Briggs Morrison, MD (1)  ·  Dale Bixby, M.D., Ph.D. (1)  ·  David Snyder, M.D. (1)  ·  David Wald, MD, PhD (1)  ·  Ehab Atallah, MD (1)

Results publications

PMID 16990776, PMID 21145590, PMID 21540460, PMID 22047558, PMID 22825216, PMID 22987312, PMID 24060561, PMID 24355079, PMID 24753538, PMID 25394714, PMID 26072403, PMID 26639404, PMID 27927766, PMID 33635333, PMID 35982483, PMID 38467031, PMID 38683966, PMID 39570620, PMID 40298994

NIH funding

2009 (1), 2023 (1)